Recombinant zoster vaccine
Phase 3Vaccine
Recombinant zoster vaccine is one of 126 biologic programs targeting Herpes Zoster. It is currently in Phase 3.
6
Indications
11
Total Trials
8
Active Trials
125
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
145 competitors in Multiple Sclerosis
#DrugCompanyPhaseTrials
1Cytoxan
BBaxter Healthcare Corporation
Phase 3
Versed
CConrado Roberto Hoffmann Filho
Phase 3
Questran
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Vumerity
BiogenPhase 3
Frexalimab
SanofiPhase 3
Clemastine Fumarate
NovartisPhase 3
Activated Charcoal
SanofiPhase 3
Mayzent
NovartisPhase 3
Antihistamine
Arrowhead PharmaceuticalsPhase 3
Recombinant zoster vaccine
MMAXVAX Biotechnology Limited Liability Company
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Recombinant Zoster Vaccine3 trials
Efficacy, Safety and Immunogenicity Study of Recombinant Zoster Vaccine(CHO Cell) in Adults Aged 40 Years and Older
Active, not recruiting·MMAXVAX Biotechnology Limited Liability Company·Phase 3·NCT06447779·25,000 enrolled
A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell)
Active, not recruiting·MMAXVAX Biotechnology Limited Liability Company·Phase 3·NCT07293065·12,000 enrolled
Herpes Zoster3 trials
Phase III Clinical Trial of Lot-to-lot Consistency of Recombinant Herpes Zoster Vaccine (CHO Cell).
Not yet recruiting·MMAXVAX Biotechnology Limited Liability Company·Phase 3·NCT06654700·1,200 enrolled
Multiple Sclerosis1 trial
Solid Organ Transplant Recipients1 trial
Recombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients
Enrolling by invitation·—·Phase 4·NCT06162494·80 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Recombinant zoster vaccine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details